LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Stemline Therapeutics, Inc. (“Stemline” or the “Company”) (Nasdaq: STML). Investors who purchased or otherwise acquired Stemline shares between January 19, 2017 and February 1, 2017 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 4, 2017 lead plaintiff deadline.
If you are a shareholder who suffered a loss during the Class Period, click here to participate. In addition, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at email@example.com.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
On February 2, 2017, Bloomberg announced that a patient in a clinical trial of Stemline’s cancer drug SL-401 died from a severe side effect. This is the third death related to SL-401 toxicity.
When this information was released to the public, the value of Stemline fell sharply, causing investors harm.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.